<DOC>
	<DOCNO>NCT02488759</DOCNO>
	<brief_summary>The purpose study investigate safety effectiveness Nivolumab , Nivolumab combination therapy , treat patient virus-associated tumor . Certain virus know play role tumor formation growth . This study investigate effect study drug , patient follow types tumor : - Anal canal cancer - Cervical cancer - Epstein Barr Virus ( EBV ) positive gastric cancer - HPV positive negative squamous cell cancer head neck ( SCCHN ) - Merkel Cell Cancer - Nasopharyngeal cancer ( NPC ) - Penile cancer - Vaginal vulvar cancer</brief_summary>
	<brief_title>An Investigational Immuno-therapy Study Investigate Safety Effectiveness Nivolumab , Nivolumab Combination Therapy Virus-associated Tumors</brief_title>
	<detailed_description />
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Histopathologic confirmation follow tumor type ( please refer protocol full detail pertain eligible tumor type ) : 1 . Merkel Cell Carcinoma 2 . Gastric GastroEsophageal junction carcinoma 3 . Nasopharyngeal Carcinoma 4 . Squamous cell carcinoma cervix , vagina , vulva 5 . Squamous cell carcinoma Head Neck 6 . Squamous cell carcinoma anal canal penile Measurable disease CT MRI Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patient willing comply provide tumor tissue ( archival fresh biopsy specimen ) Men woman age 18 old Active brain metastasis leptomeningeal metastasis Patients active , know suspected autoimmune disease Patients condition require systemic treatment either corticosteroid immunosuppressive medication Patients hepatitis Patients HIV Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>